At Least 97,000 Children in the U.S. Tested Positive in Last 2 Weeks of July

This briefing has ended. Read reside coronavirus updates right here.

The C.D.C. said that from early March through late July, it received reports of 570 young people — ranging from infants to age 20 — who met the definition of MIS-C. Most of those patients were previously healthy, the report said.

About 40 percent were Hispanic or Latino; 33 percent were Black and 13 percent were white, the report said. Ten died and nearly two-thirds were admitted to intensive care units, it said. Symptoms include a fever, rash, pinkeye, stomach distress, confusion, bluish lips, muscle weakness, racing heart rate and cardiac shock.

Governor DeWine got the positive result when he was screened before President Trump arrived in Ohio for campaign appearances.

That test was an antigen test manufactured by the diagnostic health care company Quidel, one of two such tests given emergency use authorization by the Food and Drug Administration. These tests, while fast and convenient, are known to be less accurate than PCR tests, which were used to retest Governor DeWine twice on Thursday and once more on Saturday. All three PCR tests came back negative, confirming that the governor is not infected.

His experience could raise concerns about how much states will rely on antigen tests to augment other forms of testing that are in short supply. Ohio is one of seven states that said this week that they were banding together to purchase a total of 3.5 million rapid coronavirus tests, including antigen tests, along with other vital supplies. Governor DeWine said on CNN Sunday that he had already been in touch with Gov. Larry Hogan of Maryland to talk about the tests and the seven-state agreement.

“If anyone needed a wake-up call with antigens, how careful you have to be, we certainly saw that with my test,” Governor DeWine said. “And we’re going to be very careful in how we use it.”

He added that he would direct any funding from a new federal relief package to expanded testing and helping schools adapt.

“We have doubled our testing in the last four weeks,” he said. “We need to double it again and then double it again. And so that is not going to be cheap to do.”

PCR tests are in short supply nationwide, and turnaround times for results have stretched past two weeks in some parts of the country, rendering the information useless.

“The downside of executive orders is, you can’t address some of the small business incidents that are there,” said Mark Meadows, the White House chief of staff, in a prerecorded interview that was broadcast Sunday on Gray Television. “You can’t necessarily get direct payments, because it has to do with appropriations. That’s something that the president doesn’t have the ability to do. So, you miss on those two key areas. You miss on money for schools. You miss on any funding for state and local revenue needs that may be out there.”

Like many communities, Kansas City, Mo., has been having a tough time lately, and it will get tougher if Congress and the White House can’t reach a deal on more aid, the city’s mayor, Quinton Lucas, said on Sunday.

Dr. Deborah Birx, the White House coronavirus coordinator, recently named Kansas City as one of 10 potential coronavirus hot spots around the country because of troubling signs in its testing data. Daily case counts have been declining, but the city is experiencing huge backlogs in testing that are delaying results by as much as two weeks, making them nearly useless in heading off the spread of the disease.

What will it take to address the problem? “Money,” Mr. Lucas said Sunday on the CBS program “Face the Nation.” “We need more resources to get more testing, to get faster testing through.”

Kansas City’s Covid-19 response has already cost the city millions, and without federal aid, a growing budget deficit may soon force officials to start furloughing workers and eliminating jobs.

“This isn’t just theoretical for us,” he said. “These are issues that are significant and in the now, and so we are looking for a deal.”

Kansas City has delayed the start of its school year until after Labor Day to buy more time to make its schools safe to reopen. But the schools need more money to buy protective equipment and implement social distancing measures, Mr. Lucas said.

He said it was difficult to make the right decisions locally without clear guidance from the federal government: “I’m a lawyer by training. I talk to doctors and health care professionals here, but these are calls necessarily that sometimes mayors may not be equipped to make, or some governors.”

With the number of severely ill patients rising and with remdesivir, the only drug shown to speed recovery, in short supply, an urgent need to quickly increase remdesivir production has arisen. Some U.S. hospitals have been forced to ration the drug, using various systems to decide who should get it.

Now, in a rare agreement between drug companies, Pfizer has entered into an agreement with Gilead Sciences, the maker of remdesivir, to manufacture the drug at a facility in Kansas. It is meant to be part of an effort to quickly increase the drug’s supply.

Pfizer will be one of 40 companies in North America, Europe and Asia that will be making the drug. Gilead says it plans to produce more than two million courses of treatment by the end of 2020. It says it also will produce another several million doses of remdesivir in 2021 if they are needed.

Remdesivir is an anti-viral drug that failed as a treatment for hepatitis C but was tested in Covid-19 patients because it seemed effective against the virus in laboratory studies and because its safety had already been determined. It is supplied intravenously.

The evidence of its effectiveness against the new coronavirus comes from a federal study of 1,000 hospitalized patients who received remdesivir or a placebo. Preliminary results were announced on April 27, and on May 1, the Food and Drug Administration gave the drug emergency use authorization, allowing Gilead to sell remdesivir even though it has not yet been approved. The price for a five-day course is $3,120.

Gilead explains the supply problems by saying it is difficult and time consuming to make remdesivir. The company says manufacturing is “a long, linear chemical synthesis process that must be completed sequentially and includes several specialized chemistry steps and novel substances with limited global availability.”

Radhika Kumar goes to work every morning hoping to save lives. As a contact tracer for Los Angeles County, her job, at least on paper, entails phoning people who have tested positive for the coronavirus, along with others they may have exposed, and providing them with guidance on how to isolate so as not to infect others.

If that sounds easy, it is not.

To persuade people to cooperate, she has to get them to trust her. She has to convince them that they might be infected, even if they have no symptoms. She has to let people curse at her and hang up, then she has to call them back the next day.

And if she wants them to heed her advice, she has to listen, really listen, to how scared they are that if they stay home from their jobs, they might not be able to feed their families.

“Sometimes it can really get to you,” she said. “The other day I had one young lady, and she was screaming on the phone, ‘You don’t understand — I have three kids. I have to go to work.’”

“I kept calling back and calling back,” Ms. Kumar said. “I’m very relentless like that. I thought about it all night — what am I going to do? I called her again first thing in the morning, and I was so relieved when she picked up.”

Even as officials at the Centers for Disease Control and Prevention continue to tout the effectiveness of contact tracing, and state and local health agencies across the United States deploy new armies of tracers, tracking down everyone with the coronavirus is proving to be a Sisyphean task.

France is imposing a new requirement that people wear face masks outdoors in crowded areas of Paris and other major cities beginning on Monday as the number of coronavirus infections rises at the fastest rate since a national quarantine ended in mid-May.

The country had gotten the number of infections under control, but the pandemic is creeping back, with 2,288 new Covid-19 cases reported on Friday — the third consecutive day of sharp increase. In the Paris Ile-de-France region, the rate of infections reached 2.4 percent on Friday, compared with a 1.6 percent national average.

The rise of new clusters has led the government to warn of the possibility of a second wave of infections in the autumn. In an effort to stem the spread of the virus, masks will now be mandatory for people age 11 and above in high-traffic areas, from the tourist havens of Saint Tropez and Biarritz to the Seine river in Paris, Montmartre and other popular sites, as well as at outdoor food markets and in Paris’s crowded suburbs.

The police will be enforcing the measures — which will be in place for at least a month in Paris and are subject to review in other areas — with a fine of 135 euros ($159).

The authorities are especially concerned about the popularity of “free parties,” in which hundreds of young people gather in the Parisien woods and other areas, often without wearing masks.

Wearing a mask in crowded enclosed spaces, including museums, shopping malls and on public transportation, has been compulsory in France since mid-July.

Here is what else is happening around the world:

  • At least nine people were killed after a fire broke out on Sunday at a hotel in southern India that was being used as a makeshift facility for Covid-19 patients, officials said. The police attributed the accident to a short circuit in an air-conditioner on the ground floor of the Swarna Palace.

  • New Zealand on Sunday marked 100 days without any new reported cases of local transmission of the coronavirus, a milestone as the pandemic continues to devastate countries across the world. New Zealand, a nation of five million people, reported in March that it had stamped out the virus after strict lockdown measures were implemented. Dr. Ashley Bloomfield, the country’s top health official, said it was “a significant milestone” but added “we can’t afford to be complacent.”


In 2009, when H1N1, better known as swine flu, was stoking fears of a devastating pandemic, a small biotech company named Inovio Pharmaceuticals rushed to create a vaccine. After announcing promising early results, the company’s stock soared more than 1,000 percent.

In the years since, Inovio has announced encouraging news about its work on vaccines for malaria, the Zika virus and even a “cancer vaccine.” The declarations have caused the company’s stock price to leap, enriching investors and senior executives.

There is a catch, though: Inovio has never brought a vaccine to market.

Now, Inovio is working on a vaccine for the coronavirus, and a flurry of positive news releases about its funding and preliminary results have helped the company attract money from the U.S. government and investors.

But some scientists and financial analysts question the viability of Inovio’s technology. While there are some early signs of promise with its vaccine, Inovio has released only bare-bones data from the first phase of clinical trials. It is locked in a legal battle with a key manufacturing partner that claims Inovio stole its technology.

And while the company has said that it is part of Operation Warp Speed — the flagship federal effort to quickly produce treatments and vaccines for the coronavirus — Inovio is not on the list of companies selected to receive financial support to mass-produce vaccines.

“The absence of that funding, coupled with their ongoing litigation, coupled with the need to scale a device, coupled with the absence of complete Phase 1 data, makes people skeptical,” said Stephen Willey, an analyst at Stifel, an investment firm.

Inovio could provide an update on its progress with the vaccine when it releases its second-quarter financial results on Monday.

In other business news:

  • Saudi Aramco, the world’s largest oil company, said on Sunday that its quarterly earnings had plunged more than 73 percent compared with a year ago, as lockdowns imposed to curb the pandemic drastically cut the demand for oil. Despite the steep fall in earnings, to $6.6 billion from $24.7 billion, the company said it would continue paying a quarterly dividend of $18.75 billion — nearly all of which will go to the Saudi government.

Despite the coronavirus pandemic, tens of thousands of motorcycle enthusiasts converged over the weekend outside the small South Dakota community of Sturgis for the 80th annual Sturgis Motorcycle Rally. Officials said about 250,000 enthusiasts were expected this year — about half the number who attended last year, but a figure that would still make the rally one of the country’s largest public gatherings since the first coronavirus cases emerged in the spring.

Many in attendance said they were not concerned about the virus as they walked around without masks.

On Sundays, thousands of residents of Portsmouth, N.H., find a poem nestled inside the city’s Covid-19 newsletter.

The poems, written by Tammi J. Truax, the city’s poet laureate, help offset the gloom of the pandemic while giving residents a chance to pause briefly and reflect on something other than the coronavirus.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *